TY - JOUR
T1 - Pre-Diagnosis Pain in Patients With Pancreatic Cancer Signals the Need for Aggressive Symptom Management
AU - Mcnearney, Terry A.
AU - Digbeu, Biai Dominique Elmir
AU - Baillargeon, Jacques G.
AU - Ladnier, Dennis
AU - Rahib, Lola
AU - Matrisian, Lynn M.
N1 - Publisher Copyright:
© 2023 The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Objective: This study assessed the impact of pancreatic cancer (PC) pain on associated symptoms, activities, and resource utilization from 2016 to 2020 in an online patient registry. Patients and Methods: Responses from PC patient volunteers (N = 1978) were analyzed from online surveys in a cross-sectional study. Comparisons were performed between PC patient groups reporting, (1) the presence vs. absence of pre-diagnosis PC pain, (2) high (4-8) vs. low (0-3) pain intensity scores on an 11-point numerical rating scale (NRS), and (3) year of PC diagnosis (2010-2020). Descriptive statistics and all bivariate analyses were performed using Chi-square or Fisher's Exact tests. Results: PC pain was the most frequently reported pre-diagnosis symptom (62%). Pre-diagnostic PC pain was reported more frequently by women, those with a younger age at diagnosis, and those with PC that spread to the liver and peritoneum. Those with pre-diagnostic PC pain vs. those without reported higher pain intensities (2.64 ± 2.54 vs.1.56 ± 2.01 NRS mean ± SD, respectively, P =. 0039); increased frequencies of post-diagnosis symptoms of cramping after meals, feelings of indigestion, and weight loss (P =. 02-.0001); and increased resource utilization in PC pain management: (ER visits N = 86 vs. N = 6, P =. 018 and analgesic prescriptions, P <. 03). The frequency of high pain intensity scores was not decreased over a recent 11-year span. Conclusions: PC pain continues to be a prominent PC symptom. Patients reporting pre-diagnosis PC pain experience increased GI metastasis, symptoms burden, and are often undertreated. Its mitigation may require novel treatments, more resources dedicated to ongoing pain management and surveillance to improve outcomes.
AB - Objective: This study assessed the impact of pancreatic cancer (PC) pain on associated symptoms, activities, and resource utilization from 2016 to 2020 in an online patient registry. Patients and Methods: Responses from PC patient volunteers (N = 1978) were analyzed from online surveys in a cross-sectional study. Comparisons were performed between PC patient groups reporting, (1) the presence vs. absence of pre-diagnosis PC pain, (2) high (4-8) vs. low (0-3) pain intensity scores on an 11-point numerical rating scale (NRS), and (3) year of PC diagnosis (2010-2020). Descriptive statistics and all bivariate analyses were performed using Chi-square or Fisher's Exact tests. Results: PC pain was the most frequently reported pre-diagnosis symptom (62%). Pre-diagnostic PC pain was reported more frequently by women, those with a younger age at diagnosis, and those with PC that spread to the liver and peritoneum. Those with pre-diagnostic PC pain vs. those without reported higher pain intensities (2.64 ± 2.54 vs.1.56 ± 2.01 NRS mean ± SD, respectively, P =. 0039); increased frequencies of post-diagnosis symptoms of cramping after meals, feelings of indigestion, and weight loss (P =. 02-.0001); and increased resource utilization in PC pain management: (ER visits N = 86 vs. N = 6, P =. 018 and analgesic prescriptions, P <. 03). The frequency of high pain intensity scores was not decreased over a recent 11-year span. Conclusions: PC pain continues to be a prominent PC symptom. Patients reporting pre-diagnosis PC pain experience increased GI metastasis, symptoms burden, and are often undertreated. Its mitigation may require novel treatments, more resources dedicated to ongoing pain management and surveillance to improve outcomes.
KW - health-related quality of life
KW - outcomes
KW - pain morbidity
KW - pancreatic cancer pain
KW - symptom burden
UR - http://www.scopus.com/inward/record.url?scp=85179838836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85179838836&partnerID=8YFLogxK
U2 - 10.1093/oncolo/oyad153
DO - 10.1093/oncolo/oyad153
M3 - Article
C2 - 37285228
AN - SCOPUS:85179838836
SN - 1083-7159
VL - 28
SP - e1185-e1197
JO - Oncologist
JF - Oncologist
IS - 12
ER -